RxDoctor Payments Data

Alfred Tinger, MD

Radiation Oncology · Yonkers, NYNPI 1760470173

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,975 of the $3,771 with a category attached, or 78.9%. It is spread thinly across 22 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,018 and has fallen 87.4% since, to $128 in 2025.

$3,771in general payments, 2019–2025

Across 50 payments — averaging $75.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$790
  • Sanofi$387
  • Lilly USA, LLC$299
  • Novocure Inc.$289
  • E.r. Squibb & Sons, L.L.C.$279
  • Astellas Pharma US Inc$270
  • plus $1K from 16 others
$15,360in research payments, 2019–2025

Across 2 payments — averaging $7680.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure Inc.$15K

What the payments were for

  • Travel & lodging$79021%
  • Food & beverage$2,97579%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,771 in reported general payments places this provider in the 80th percentile of 397 radiation oncology providers in New York.

See all radiation oncology providers in New York

Medicare billing

Part B allowed, 2024
$85,710
Medicare patients
170
Services billed
1,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl34$513
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$427
Bicalutamide28$396
Dexamethasone13$229
Lidocaine Hcl ViscousLidocaine Hcl13$188
Gabapentin15$166
Paroxetine Hcl13$51
Venlafaxine Hcl ErVenlafaxine Hcl18$47

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →